SCHEMBL1966151

SCHEMBL1966151

CC(=O)Nc1ccc(C(=O)O)c(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.58
NPC1 O15118 4/20 0.53
MYC P01106 1/20 0.53
RARA P10276 2/20 0.52
RARB P10826 2/20 0.52
RARG P13631 1/20 0.52
KDM4E B2RXH2 2/20 0.51
RAB9A P51151 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
MPO P05164 1/20 0.50
PREP P48147 1/20 0.50
POLB P06746 1/20 0.49
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
NAPRT Q6XQN6 1/20 0.47
HSD17B10 Q99714 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2983642 0.87 HDAC1 (0.60) HDAC1NPC1RARGKDM4ERAB9A
SCHEMBL1655468 0.86 MYC (0.56) HDAC1NPC1MYCRARGKDM4E
SCHEMBL15790439 0.85 RARA (0.51) HDAC1NPC1RARARARBRARG
SCHEMBL2925453 0.84 HDAC1 (0.61) HDAC1NPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL28504512 0.83 KMT2A (0.53) HDAC1NPC1RARARARBRARG
SCHEMBL2500845 0.83 MYC (0.61) NPC1MYCRARGKDM4ERAB9A
SCHEMBL15598651 0.83 SMN1; SMN2 (0.69) HDAC1NPC1KDM4ERAB9ASMN1; SMN2
SCHEMBL10033272 0.83 RARA (0.50) HDAC1NPC1RARARARBRARG
SCHEMBL2432970 0.81 RARB (0.48) HDAC1NPC1RARARARBRARG
SCHEMBL9821067 0.81 POLB (0.69) HDAC1NPC1RAB9ASMN1; SMN2CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230026271-A1 Piperazine Compounds for Inhibiting CPS1 EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-01-26 US disclosed
EP-4061803-A1 PIPERAZINE COMPOUNDS FOR INHIBITING CPS1 Eisai R&D Management Co., Ltd. (JP) 2022-09-28 EP disclosed
CN-114981247-A Piperazine compounds for inhibiting CPS1 卫材R&D管理有限公司 2022-08-30 CN disclosed
US-11377423-B2 Inhibitors of histone deacetylase THE BROAD INSTITUTE, INC. (US) 2022-07-05 US disclosed
WO-2021102300-A1 PIPERAZINE COMPOUNDS FOR INHIBITING CPS1 EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-05-27 WO disclosed
EP-2877444-B1 INHIBITORS OF HISTONE DEACETYLASE BROAD INST INC (US) 2020-09-02 EP disclosed
US-20180072671-A1 INHIBITORS OF HISTONE DEACETYLASE THE BROAD INSTITUTE, INC. (US) 2018-03-15 US disclosed
US-9790184-B2 Inhibitors of histone deacetylase THE BROAD INSTITUTE, INC. (US) 2017-10-17 US disclosed
US-20150191427-A1 INHIBITORS OF HISTONE DEACETYLASE THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) 2015-07-09 US disclosed
EP-2877444-A1 INHIBITORS OF HISTONE DEACETYLASE The Broad Institute, Inc. (US) 2015-06-03 EP disclosed
US-8916599-B2 1H-benz imidazole-5-carboxamides as anti-inflammatory agents OREXO AB (SE) 2014-12-23 US disclosed
WO-2014018979-A1 INHIBITORS OF HISTONE DEACETYLASE THE BROAD INSTITUTE, INC. (US) 2014-01-30 WO disclosed
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed
CN-102224143-A 1h-benzimidazole-5-carboxamides as anti-inflammatory agents BOEHRINGER INGELHEIM INT 2011-10-19 CN disclosed
EP-2334652-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS Boehringer Ingelheim International GmbH (DE) 2011-06-22 EP disclosed
WO-2010034796-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed
US-4333940-A Ring-fluorinated 4-(monosubstituted-amino) phenyl compounds in inhibiting atherosclerotic lesion development AMERICAN CYANAMID COMPANY (US) 1982-06-08 US disclosed
US-4243609-A ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS AMERICAN CYANAMID COMPANY (US) 1981-01-06 US disclosed
EP-0003663-A2 Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them AMERICAN CYANAMID COMPANY (US) 1979-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026271-A1 Piperazine Compounds for Inhibiting CPS1 CPS1, CPSF1, CPSF7 HDAC1 227/4885NPC1 887/4885MYC 1581/4885
US-20110312935-A1 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents MAPRE2, MAPRE1, H1-4 HDAC1 78/4885NPC1 4650/4885MYC 484/4885
US-20180072671-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC3, HDAC1, HDAC11 HDAC1 2/4885NPC1 56/4885MYC 3058/4885
US-20150191427-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC3, HDAC1, HDAC5 HDAC1 2/4885NPC1 61/4885MYC 3049/4885
US-11377423-B2 Inhibitors of histone deacetylase HDAC3, HDAC1, HDAC11 HDAC1 2/4885NPC1 59/4885MYC 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.